【24h】

Angiopoietin balance in septic shock patients treated by direct hemoperfusion with polymyxin b-immobilized fiber.

机译:脓毒症休克患者的血管生成素平衡,直接用固定化多粘菌素b的纤维进行血液灌流治疗。

获取原文
获取原文并翻译 | 示例
       

摘要

Capillary permeability is a tightly regulated feature of microcirculation in all organ beds; however, in sepsis this feature is fundamentally altered. We previously reported elevated levels of vascular endothelial growth factor and its receptor (fms-like tyrosine kinase-1) in patients with septic shock, then investigated two kinds of angiopoietins in those patients. An enzyme-linked immunoassay was used to measure serum angiopoietin-1 and -2 levels in 12 patients with septic shock who were treated by direct hemoperfusion with a polymyxin B-immobilized fiber column (DHP-PMX). The angiopoietin-1 level was lower in patients with septic shock (7.01 +/- 10.08 ng/mL) than in controls (28.24 +/- 11.61 ng/mL, P < 0.001), but the angiopoietin-2 level was higher in septic shock patients (40.83 +/- 30.13 ng/mL vs. 2.47 +/- 1.78 ng/mL, P < 0.001). Between seven survivors and five non-survivors there was no significant difference in angiopoietin-1 levels before DHP-PMX therapy. During DHP-PMX therapy, however, the angiopoietin-2 level was significantly decreased in survivors (31.52 +/- 26.15 ng/mL vs. 17.32 +/- 22.46 ng/mL, P = 0.035). Moreover, at the end of the therapy, the angiopoietin-1 level was significantly lower in non-survivors (1.14 +/- 1.30 ng/mL vs. 10.43 +/- 13.56 ng/mL, P = 0.042), but the angiopoietin-2 level in non-survivors was significantly higher (70.79 +/- 40.47 ng/mL vs. 17.32 +/- 22.46 ng/mL, P = 0.019). The angiopoietin-2 level may be associated with vascular permeability in septic patients, and angiopoietins may be suitable markers of disease severity and mortality.
机译:毛细管渗透性是所有器官床中微循环的严格调节特征。但是,在败血症中,此功能已被根本改变。我们先前曾报道败血性休克患者血管内皮生长因子及其受体(fms样酪氨酸激酶-1)水平升高,然后研究了这些患者中的两种血管生成素。酶联免疫测定法用于测量12例败血性休克患者的血清血管生成素-1和-2的水平,这些患者采用固定有多粘菌素B的纤维柱(DHP-PMX)进行直接血液灌流治疗。败血性休克患者的血管生成素-1水平(7.01 +/- 10.08 ng / mL)低于对照组(28.24 +/- 11.61 ng / mL,P <0.001),但败血性休克患者的血管生成素-2水平较高。休克患者(40.83 +/- 30.13 ng / mL与2.47 +/- 1.78 ng / mL,P <0.001)。在DHP-PMX治疗之前,在7名幸存者和5名非幸存者之间,血管生成素1水平没有显着差异。然而,在DHP-PMX治疗期间,幸存者的血管生成素2水平显着降低(31.52 +/- 26.15 ng / mL与17.32 +/- 22.46 ng / mL,P = 0.035)。此外,在治疗结束时,非存活者的血管生成素-1水平显着降低(1.14 +/- 1.30 ng / mL与10.43 +/- 13.56 ng / mL,P = 0.042),但血管生成素-非存活者的2水平显着更高(70.79 +/- 40.47 ng / mL与17.32 +/- 22.46 ng / mL,P = 0.019)。败血病患者的血管生成素2水平可能与血管通透性有关,血管生成素可能是疾病严重程度和死亡率的合适指标。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号